Dietmar Berger, Sanofi CMO
Sanofi’s next-gen hemophilia drugs take a PhIII bow — but can they still make their mark at this stage?
Back in early 2018, when Sanofi put up $11.6 billion to buy Bioverativ and its hemophilia drugs Eloctate and Alprolix, the deal looked out …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
